RLAY Stock — Relay Therapeutics Inc.: Cash, EV, Pipeline

Share price

$18.84

Market cap

$4,128.6M

Cash

$910.9M

Enterprise value

$3,217.7M

Balance sheet

Cash	$910.9M
Debt	$0.0M
Net cash	$910.9M
Enterprise value	$3,217.7M
Basic shares	218.5M shares
Fully diluted shares	247.9M shares
Fully diluted market cap	$4,670.8M
Cash per share	$4.17

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading RLAY daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jun 11 - Jul 23	RLY-2608	Phase 1	PIK3CA Mutation; Solid Tumor, Adult; HER2-negative Breast Cancer	—
Feb 10 - Mar 23	RLY-8161	Phase 1	Advanced NRAS-Mutant Melanoma; Advanced NRAS-Mutant Solid Tumors; NRAS Mutation	—
Jun 11 - Jul 23	Zovegalisib	Phase 3	PIK3CA Mutation; HER2- Negative Breast Cancer; Hormone Receptor Positive Tumor	—
Aug 12 - Sep 23	RLY-2608	Phase 2	PIK3CA-Related Overgrowth Spectrum (PROS); Lymphatic Malformations; Vascular Malformations	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Zovegalisib

Phase 3 · Active Modality: allosteric pan-mutant isoform-selective PI3K-alpha inhibitor

Aliases RLY-2608

Target PI3K-alpha

Indications

PIK3CA-mutated HR+/HER2- advanced breast cancer (with fulvestrant) (Phase 3)
PIK3CA-related overgrowth spectrum and vascular anomalies (Phase 1)

Status note ReDiscover-2 global Phase 3 registrational study initiated Q2 2025; ReInspire Phase 1/2 in PROS/vascular anomalies enrolling.

RLY-8161

Stage not disclosed · Active Modality: NRAS-selective inhibitor

Target NRAS

Indications

NRAS-mutant melanoma (Stage not disclosed)
NRAS-mutant solid tumors (Stage not disclosed)

Status note Clinical trial initiated; phase not stated in filing.

Fabry disease non-inhibitory chaperone

Discovery · Active Modality: non-inhibitory chaperone

Target alpha-galactosidase A

Indications

Fabry disease (Discovery)

Status note Research-stage program.

Lirafugratinib

Stage not disclosed · Active Modality: selective oral small-molecule FGFR2 inhibitor

Aliases RLY-4008

Target FGFR2

Partnerships Elevar Therapeutics (exclusive global development and commercialization rights)

Indications

FGFR2-driven cholangiocarcinoma (Stage not disclosed)

Status note Elevar responsible for all further development and global commercialization; Relay retains up to $485M in milestones and tiered royalties.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Zovegalisib
Lead indication	PIK3CA Mutation
Lead phase	Phase 3
Active trials	4

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06982521	Phase 3	Recruiting	Sponsor	RLAY	—	PIK3CA Mutation; HER2- Negative Breast Cancer; Hormone Receptor Positive Tumor	—
NCT06789913	Phase 2	Recruiting	Sponsor	RLAY	—	PIK3CA-Related Overgrowth Spectrum (PROS); Lymphatic Malformations; Vascular Malformations	—
NCT05216432	Phase 1	Recruiting	Sponsor	RLAY	—	PIK3CA Mutation; Solid Tumor, Adult; HER2-negative Breast Cancer	—
NCT07584226	Phase 1	Recruiting	Sponsor	RLAY	—	Advanced NRAS-Mutant Melanoma; Advanced NRAS-Mutant Solid Tumors; NRAS Mutation	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for Relay Therapeutics, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Baker Bros. Advisors	2,826,783	+1,666,666	0.27%	2026-08-14
Frazier Life Sciences	1,015,693	+1,015,693	0.41%	2026-08-14
ADAR1 Capital Management	358,333	+358,333	0.32%	2026-08-14
Logos Global Management	350,000	-400,000	0.28%	2026-08-14
Sphera Biotech	233,836	-174,600	0.63%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

RLAY — Relay Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders